Sujin Yang

Sujin Yang

Auto-generated profile, based on publicly available information

Sujin Yang

Department of Breast Surgery The First Affiliated Hospital with Nanjing Medical University Nanjing China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Gene
Verified
Journal Article
Closed access
SYSu-Jin Yang
Su-Jin Yang
DWDan-Dan Wang
Dan-Dan Wang
JLJian Li
Jian Li
HXHan-Zi Xu
Han-Zi Xu
HSHong-Yu Shen
Hong-Yu Shen
JTJin-Hai Tang
Jin-Hai Tang

22 January 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
JWJinyan Wang
Jinyan Wang
QZQian Zhang
Qian Zhang
DWDandan Wang
Dandan Wang
SYSujin Yang
Sujin Yang
SZSiying Zhou
Siying Zhou
JFJifeng Feng
Jifeng Feng

10 January 2020 in Epigenomics
Verified
Journal Article
Closed access
SZSi-Ying Zhou
Si-Ying Zhou
WCWei Chen
Wei Chen
SYSu-Jin Yang
Su-Jin Yang
JLJian Li
Jian Li
JZJun-Ying Zhang
Jun-Ying Zhang
JTJin-Hai Tang
Jin-Hai Tang
Aim: We aimed to explore the roles of circular RNA, circVAPA in regulating cell migration and invasion of breast cancer. Materials & methods: CircVAPA expression was detected in breast cancer tissues and cells. The role of circVAPA was evaluated by MTT assay, wound-healing and transwell assay. The relationship between circVAPA and miR-130a-5p and the location of circVAPA were explored. Results: We discovered that circVAPA was dysregulated in breast cancer tissues and cells. Ectopic circVAPA regulated breast cancer migration, invasion and proliferation. CircVAPA was mainly expressed in the cytoplasm and could act as a miRNA sponge for miR-130a-5p, but did not regulate its parental gene. Conclusion: CircVAPA may promote migration and invasion capacity of breast cancer via harboring miR-130a-5p.

10 January 2020 in Epigenomics
Verified
Journal Article
Closed access
SYSu-Jin Yang
Su-Jin Yang
DWDan-Dan Wang
Dan-Dan Wang
SZSi-Ying Zhou
Si-Ying Zhou
QZQian Zhang
Qian Zhang
JWJin-Yan Wang
Jin-Yan Wang
JTJinhai Tang
Jinhai Tang
Aim: Circular RNAs (circRNAs) still have many potential functions in the process of tumor development that are not completely understood. The study aims to explore novel circRNAs and their mechanis...

19 December 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SZShanliang Zhong
Shanliang Zhong
HXhanzi xu
hanzi xu
DWDandan Wang
Dandan Wang
SYSujin Yang
Sujin Yang
HLHuixin Li
Huixin Li
SZSiying Zhou
Siying Zhou

12 June 2025 in Cancer Science
Verified
Journal Article
Open access
SYSujin Yang
Sujin Yang
MYMei Yang
Mei Yang
QSQuanfeng Shao
Quanfeng Shao
DWDandan Wang
Dandan Wang
SZShanliang Zhong
Shanliang Zhong
WCWei-xian Chen
Wei-xian Chen
Anthracycline resistance represents a critical therapeutic challenge in breast cancer treatment, wherein alterations in the tumor immune microenvironment and enhanced cellular resistance mechanisms facilitate chemoresistance progression. Transcriptome analysis of 142 HER2‐negative breast cancer patients undergoing anthracycline‐based chemotherapy revealed four distinct tumor‐infiltrating cell subtypes, with subtype D exhibiting elevated M1 macrophage infiltration and superior prognostic outcomes. Differential expression analysis identified miR‐222 as the predominantly upregulated microRNA in adriamycin‐resistant cells, while Tandem Mass Tag mass spectrometry‐based quantitative analysis elucidated PTEN as its direct target and FN1 as a crucial downstream mediator. Engineered extracellular vesicles (EVs) carrying a miR‐222 inhibitor were developed to reverse adriamycin resistance via PTEN/FN1 signaling modulation. Molecular docking analysis found specific PTEN‐FN1 protein interactions characterized by stable hydrogen bonds at ARG142‐ASP23 and ARG15‐GLU95. In xenograft models, EVs‐mediated delivery of the miR‐222 inhibitor significantly attenuated MCF‐7/ADR tumor progression through miR‐222 suppression and PTEN restoration, with concordant molecular alterations observed in serum‐derived EVs. Our findings establish a novel mechanism of EVs‐mediated drug resistance through the microRNA‐222/PTEN/FN1 axis and present Engineered EVs as a promising therapeutic strategy for anthracycline resistance in breast cancer, while highlighting circulating EVs profiles as potential treatment monitoring biomarkers.